Novo Nordisk's weight loss and diabetes medication semaglutide, the active ingredient in both Wegovy and Ozempic, has been shown to improve symptoms associated with the most common form of heart failure, adding to its list of potential benefits.

A study published on Friday looking at 529 patients found that a 2.4 milligram dose of semaglutide, approved by the Food and Drug Administration for weight loss, improved patients' symptoms of heart failure by nearly 17 points on a 100 point scale, almost 8 points more than those on a placebo.

NIKKI HALEY CLAIMED DEBATE SPOTLIGHT AMONG CROWD OF 'SCREAMING MEN'

Study patients on the high dose of semaglutide also decreased their body weight by 13.3% and improved the distance that they were able to walk in six minutes by over 20 meters.

The Danish pharmaceutical giant, which has had record profits from both Ozempic and Wegovy this year, partially funded the study, which adds to the mounting evidence that semaglutide might have various health benefits.

Earlier this month, another Novo Nordisk study found that Wegovy had the potential to prevent 1.5 million cardiovascular events, such as heart attacks and strokes, in the United States over 10 years.

Another independent study released on Aug. 8 found that Wegovy lowered adverse cardiovascular events by 20% in patients worldwide.

Novo Nordisk stock prices on Aug. 8 increased by nearly 30 points to $189.17 per share. This week, the highest price of Novo Nordisk stock was $192 per share.

CLICK HERE TO READ MORE FROM THE WASHINGTON EXAMINER

Novo Nordisk and American competitor Eli Lilly, the maker of the diabetes drug Mounjaro that also hopes to gain FDA approval for a similar weight loss medication in the coming weeks, are both being sued for possible gastrointestinal complications from their diabetes medication.

Both Novo Nordisk and Eli Lilly have previously told the Washington Examiner that they take patient safety very seriously.